Low urinary kallikrein rats: Different sensitivity of verapamil on hypertensive response to central acute cadmium administration

Veterinary and Human Toxicology

Volumn 45, Issue 4, 2003, Pages 202-206

  Varoni, Maria Vittoria ^a   Palomba, Domenico ^a   Satta, Michele ^a   Anania, Vittorio ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CADMIUM; KALLIKREIN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; HEMODYNAMICS; KALLIKREIN KININ SYSTEM; MALE; NONHUMAN; PATHOPHYSIOLOGY; RAT; TOXICITY TESTING; URINE LEVEL;

ACETATES; ANIMALS; BLOOD PRESSURE; CADMIUM; CALCIUM CHANNEL BLOCKERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; INJECTIONS, INTRAVENTRICULAR; KALLIKREINS; MALE; RATS; RATS, INBRED STRAINS; RATS, WISTAR; VERAPAMIL;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0037810689     PISSN: 01456296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Elinder CG: Normal values for cadmium in human tissues, blood and urine in different countries. In Friberg L, Elinder CG, Kjellström T et al eds: Cadmium and Health. A Toxicological and Epidemiological Appraisal, Vol I Exposure, Dose and Metabolism, Boca Raton, Florida: 81-102, 1985.
2. Staessen J, Lauwerys R: Health effects of environmental exposure to cadmium in a population study. J Hum Hypertens 7: 195-199, 1993.
3. Jarup L, Berglund M, Elinder CG et al: Health effects of cadmium exposure - a review of the literature and a risk estimate. Scand J Work Environ Health 55: 1-51, 1998.
4. Dudley RE, Gammal LM, Klaassen CD: Cadmium-induced hepatic and renal injury in chronically exposed rats: likely role of hepatic cadmium-metallothionein in nephrotoxicity. Toxicol Appl Pharmacol 77: 414-426, 1985.
5. Klaassen CD, Liu J: Role of metallothionein in cadmium-induced hepatotoxicity and nephrotoxicity. Drug Metab Rev 29: 79-102, 1997.
6. Buchet JP, Lauwerys R, Roels H et al: Renal effects of cadmium body burden of the general population. Lancet 336: 699-702, 1990.
7. Mueller PW, Smith SJ, Steinberg KK et al: Chronic renal tubular effects in relation to urine cadmium levels. Nephron 52: 45-54, 1989.
8. Glauser SC, Bello CT, Glauser EM: Blood cadmium level in normotensive and untreated hypertensive humans. Lancet i: 717-718, 1976.
9. Templeton DM, Cherian GM: Cadmium and hypertension. Trends Pharmacol Sci 4: 501-503, 1983.
10. Nakagawa H, Nishijo M: Environmental cadmium exposure, hypertension and cardiovascular risk. J Cardiovasc Risk 3: 11-17, 1996.
11. Staessen JA, Kuznetsova T, Roels HA et al: Exposure to cadmium and conventional and ambulatory blood pressure in a prospective population study. Public Health and Environmental Exposure to Cadmium Study Group. Am J Hypertens 13: 146-156, 2000.
12. Perry HM Jr, Erlanger MW: Sodium retention in rats with cadmium-induced hypertension. Sci Total Environ 22: 31-34, 1981.
13. Puri VN: Cadmium induced hypertension. Clin Exp Hypertens 21: 79-84, 1999.
14. Balaraman R, Gulati OD, Bhatt JD et al: Cadmium-induced hypertension in rats. Pharmacology 38: 226-34, 1989.
15. Kim JK, Choi mJK, Kim JS et al: Changes in renal function in cadmiumin-toxicated rats. Pharmacol and Toxicol 63: 342-350, 1988.
16. Madeddu P, Demontis MP, Varoni MV et al: Verapamil prevents the acute hypertensive response to intracerebroventricular cadmium in conscius normotensive rats. Am J Hypertens 6:193-197, 1993.
17. Perry HM Jr, Erlanger MW: Mechanism of cadmium-induced hypertension. Trace Substances Environ Health 9: 339-348, 1975.
18. Fadloun Z, Leach GDH: In vivo and in vitro measurement of changes in sympathetic neurone control of vascular and non-vascular tissues in rats chronically treated with Cd. Br J Pharmacol 70: 167-172, 1980.
19. Revis N: A possible mechanism for cadmium induced hypertension in rats. Life Sci 22: 479-488, 1977.
20. Brzoska MM, Moniuszko Jakoniuk J: The influence of calcium content in diet on cumulation and toxicity of cadmium in the organism. Arch Toxicol 72: 63-73, 1998.
21. Cheung WY: Calmodulin: its potential role in cell proliferation and heavy metal toxicity. Fed Proc 43: 2995-2998, 1984.
22. ++ in calmodulin. Arch Toxicol 54: 61-70, 1983.
23. - movements in synaptosomes and subcellular fractions fron rat brain and torpedo electric organ. Brain Res 323: 31-46, 1984.
24. Chao SH, Suzuki Y, Zysk JR et al: Activaction of calmodulin by various metal ions as a function of ionic radii. Mol Pharmacol 26: 75-82, 1984.
25. Sutoo D, Akiyama K: Effect of cadmium or magnesium on calcium-dependent central function that reduces blood pressure. Arch Toxicol 74: 1-4, 2000.
26. Puri VN, Tandon V: Effect of repeated administration of cadmium, captopril and its combination on plasma renin activity in rats. Pharm Res 36: 411-414, 1997.
27. Perry HM Jr, Erlanger MW: Elevated circulating renin activity in rats following doses of cadmium known to induce hypertension. J Lab Clin Med 82:399-404, 1973.
28. Demontis MP, Varoni MV, Volpe AR et al: Role of nitric oxide synthase inhibition in the acute hypertensive response to intracerebroventricular cadmium. Br J Pharmacol 123: 129-135, 1998.
29. Varoni MV, Palomba D, Satta M et al: Different response of intracerebroventricular cadmium administration on blood pressare in normal and low urinary kallikrein rats. Pharmacol Res 47: 157-162, 2003.
30. Clements JA: The glandular kallikrein family of enzimes: Tissue-specific expression and hormonal regulation. Endocr Rev 10: 393-419, 1989.
31. Keiser HR, Geller RG, Margolius HS et al: Urinary kallikrein in hypertensive animal models. Fed Proc 35: 199-202, 1976.
32. Pravanec M, Kren V, Kunes J et al: Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 17: 242-246, 1991.
33. Ferri C, Bellini C, Carlomagno A et al: Urinary kallikrein and salt sensitivity in essential hypertensive males. Kidney Int 46: 780-788, 1994.
34. Madeddu P, Varoni MV, Demontis MP et al: Urinary kallikrein: a marker of blood pressure sensitivity to salt. Kidney Int 49: 1422-1427, 1996.
35. Madeddu P, Varoni MV, Demontis MP et al: Kallikrein-kinin system and blood pressure sensitivity to salt. Hypertension 29: 471-477, 1997.
36. Madeddu P, Vio CP, Straino S et al: Renal phenotype of low kallikrein rats. Kidney Int 59: 2233-2242, 2001.
37. Buggy J, Fisher AE, Hoffman WE et al: Ventricular obstruction: effect on drinking induced by intracranial injection of Angiotensin. Science 190: 72-74, 1975.
38. Amundsen E, Putter J, Friberger P et al: Methods for the determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Adv Exp Med 102A: 83-95, 1979.
39. Lindsley CJ, Fujita K, Martins TO: The central pressor effect of bradykinin in normotensive and hypertensive rats. Hypertension 11: I126-I129, 1988.
40. Madeddu P, Glorioso N, Soro A et al: Brain kinins are responsible for the pressor effect of intracerebroventricular captopril in spontaneous hypertensive rats. Hypertension 15:407-412, 1990.